Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Revenue of Viking Therapeutics, Inc. (VKTX)
Revenue in 2023 (TTM): $
According to Viking Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Viking Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-292,000 | $-100,827,000 | $-85,895,000 | $-85,895,000 |
| 2022 | $ | $-291,000 | $-70,355,000 | $-68,867,000 | $-67,379,000 |
| 2021 | $ | $-296,000 | $-55,393,000 | $-54,990,000 | $-54,002,000 |
| 2020 | $ | $-277,000 | $-42,662,000 | $-39,495,000 | $-36,051,000 |
| 2019 | $ | $-260,000 | $-25,372,999 | $-25,779,000 | $-25,779,000 |
| 2018 | $ | $ | $4.66 M | $-22,063,000 | $-22,063,000 |
| 2017 | $ | $ | $442.88 K | $-20,577,665 | $-20,577,665 |
| 2016 | $ | $ | $1.15 M | $-14,731,822 | $-14,731,822 |
| 2015 | $ | $ | $-22,385,486 | $-23,403,988 | $-23,403,988 |
| 2014 | $ | $ | $-21,255,507 | $-21,884,183 | $-21,884,183 |
| 2013 | $ | $ | $-121,698 | $-146,247 | $-146,247 |
| 2012 | $ | $ | $-109,641 | $-444 | $-444 |